A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
Henslee
P J
PJ
Department of Medicine, University of Kentucky Medical Center, Lexington 40536-0084.
Byers
V S
VS
Jennings
C D
CD
Marciniak
E
E
Thompson
J S
JS
Macdonald
J S
JS
Romond
E H
EH
Messino
M J
MJ
Scannon
P J
PJ
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000276:immunology; D004341:Drug Evaluation; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control*; D006650:Histocompatibility Testing; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000601:surgery / Q000628:therapy; D008212:Lymphocyte Depletion; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control; D012276:Ricin / Q000276:immunology / Q000627:therapeutic use*; D013601:T-Lymphocytes
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; C068230:zolimomab aritox; D012276:Ricin